CAZ-AVI + Metronidazole + Meropenem
Phase 3Completed 0 watching 0 views this week๐ Rising
76
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Intra-Abdominal Infection
Conditions
Complicated Intra-Abdominal Infection
Trial Timeline
Mar 1, 2012 โ Apr 1, 2014
NCT ID
NCT01499290About CAZ-AVI + Metronidazole + Meropenem
CAZ-AVI + Metronidazole + Meropenem is a phase 3 stage product being developed by Pfizer for Complicated Intra-Abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01499290. Target conditions include Complicated Intra-Abdominal Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01499290 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Intra-Abdominal Infection